IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+43.34%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$350M
AUM Growth
+$350M
(+8.8%)
Cap. Flow
+$11.3M
Cap. Flow
% of AUM
3.22%
Top 10 Holdings %
Top 10 Hldgs %
41.9%
Holding
166
New
42
Increased
21
Reduced
58
Closed
16
Top Buys
| 1 |
Scholar Rock
SRRK
|
$15.4M |
| 2 |
Forte Biosciences
FBRX
|
$13.8M |
| 3 |
TG Therapeutics
TGTX
|
$8.77M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$7.36M |
| 5 |
Vir Biotechnology
VIR
|
$6.59M |
Top Sells
| 1 |
Tarsus Pharmaceuticals
TARS
|
$23.4M |
| 2 |
Soleno Therapeutics
SLNO
|
$11.2M |
| 3 |
OKUR
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
|
$6.64M |
| 4 |
Kezar Life Sciences
KZR
|
$6.47M |
| 5 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$5.76M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Tarsus Pharmaceuticals
TARS
$2.47B
| $33.6M | 4.58% | 607,689 -422,588 | -41% | -$23.4M |
|
2
Crinetics Pharmaceuticals
CRNX
$2.92B
| $26.4M | 3.59% | 516,431 +89,518 | +21% | +$4.58M |
|
|
3
Scholar Rock
SRRK
$3.14B
| $15.4M | 2.1% | +357,185 | New | +$15.4M |
|
|
BPMC
4
DELISTED
Blueprint Medicines
BPMC
| $14.8M | 2.01% | 169,374 +84,374 | +99% | +$7.36M |
|
|
5
Forte Biosciences
FBRX
$137M
| $13.8M | 1.88% | +609,225 | New | +$13.8M |
|
6
Viridian Therapeutics
VRDN
$1.5B
| $9.01M | 1.23% | 469,949 -30,028 | -6% | -$576K |
|
7
Enliven Therapeutics
ELVN
$1.2B
| $8.88M | 1.21% | 394,538 -105,028 | -21% | -$2.36M |
|
|
8
TG Therapeutics
TGTX
$4.65B
| $8.77M | 1.19% | +291,240 | New | +$8.77M |
|
9
Insmed
INSM
$28.8B
| $8.27M | 1.12% | 119,800 -35,035 | -23% | -$2.42M |
|
10
Structure Therapeutics
GPCR
$1.11B
| $7.7M | 1.05% | 284,085 +168,885 | +147% | +$4.58M |
|
11
Ultragenyx Pharmaceutical
RARE
$2.89B
| $7.53M | 1.02% | 178,989 -11 | -0% | -$463 |
|
12
Catalyst Pharmaceutical
CPRX
$2.52B
| $7.3M | 0.99% | 349,649 -68,201 | -16% | -$1.42M |
|
13
Avalo Therapeutics
AVTX
$122M
| $7.21M | 0.98% | 970,259 -100 | -0% | -$743 |
|
14
Cytokinetics
CYTK
$4.23B
| $7.06M | 0.96% | 149,982 -20,165 | -12% | -$949K |
|
|
15
Vir Biotechnology
VIR
$686M
| $6.59M | 0.9% | +897,862 | New | +$6.59M |
|
|
TECX
16
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $6.57M | 0.89% | 142,328 -124,817 | -47% | -$5.76M |
|
17
Spyre Therapeutics
SYRE
$996M
| $6.57M | 0.89% | 282,159 -20,088 | -7% | -$468K |
|
18
BridgeBio Pharma
BBIO
$9.89B
| $5.92M | 0.81% | 215,713 -69,900 | -24% | -$1.92M |
|
19
Kodiak Sciences
KOD
$478M
| $5.73M | 0.78% | 576,166 +99,580 | +21% | +$991K |
|
20
Arcus Biosciences
RCUS
$1.13B
| $5.63M | 0.77% | 378,363 -365,637 | -49% | -$5.44M |
|
|
DRUG
21
Bright Minds Biosciences
DRUG
$276M
| $5.48M | 0.75% | +152,211 | New | +$5.48M |
|
22
Eledon Pharmaceuticals
ELDN
$155M
| $4.64M | 0.63% | +1,126,637 | New | +$4.64M |
|
|
ACOG
23
Alpha Cognition Inc. Common Stock
ACOG
$134M
| $4.45M | 0.61% | +755,867 | New | +$4.45M |
|
|
LENZ
24
LENZ Therapeutics
LENZ
$1.1B
| $4.32M | 0.59% | 149,502 -55,011 | -27% | -$1.59M |
|
25
Rezolute
RZLT
$619M
| $4.2M | 0.57% | 857,230 -30,000 | -3% | -$147K |
|